Nasdaq · Healthcare
Mirum Pharmaceuticals, Inc. (MIRM)
As-reported financials and recent SEC filings for Mirum Pharmaceuticals, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$521.3M
Net income
$-23.4M
Net margin
-4.5%
Diluted EPS
$-0.47
ROE
-7.4%
P/E (TTM)
—
Market cap
$7.55B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $-22.1M | $-87.6M | $-109.2M | $-131.2M | $-173.4M |
| Net income | $-23.4M | $-87.9M | $-163.4M | $-135.7M | $-84.0M |
| Diluted EPS | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →8-K2026-06-18
View on EDGAR →1442026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →Go deeper on MIRM
Search Mirum Pharmaceuticals, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.